While preventing any type of injury is one of a soldier’s main concerns, it’s often the injuries you can’t see that prove most fatal. Injuries that are accompanied by internal bleeding and hemorrhaging account for nearly 85% of preventable deaths on the battlefield. Hopefully, Arsenal Medical has come up with a solution to help protect the people protecting our country.
Arsenal, in response to a Defense Advanced Research Projects Agency (DARPA) initiative called the Wound Stasis Program, has developed an injectable polymer foam to help stem internal bleeding from non-compressible battlefield injuries.
The Wound Stasis program was launched in 2010 in an attempt to address trauma-induced internal hemorrhaging on the battlefield. There was a clear need for a system to halt internal bleeding while soldiers could be evacuated from the conflict point and receive medical attention.
The Arsenal foam initially starts as two separate liquids that are injected into the abdominal cavity. Upon mixing, the liquids trigger a reaction that causes them to expand inside the body, covering and conforming to the injured tissue. In the process, the liquid turns into a solid foam that is able to provide pressure and halt the flow of internal bleeding until proper medical attention can be administered.
In testing, Arsenal’s new foam has been found to reduce blood loss six-fold, while increasing survival rate. Removal of the foam during surgery has also been successful, with relative ease and minimal residue.
Arsenal’s creation has not only received the green-light from DARPA for further development, but the findings were also presented at the 2012 American Associate for the Surgery of Trauma Annual Meeting to avid interest. There are currently talks of developing the technology for use in civilian and clinical scenarios as well.
Check out the animated video below for a demonstration of the products capabilities: